Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer https://www.biorxiv.org/content/10.1101/2023.04.04.535570v1?med=mas
CleverLibre Social is an inclusive social instance for open discussion, learning, and community. All cultures welcome. Hate speech and harassment strictly forbidden.